相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
D. J. McGrail et al.
ANNALS OF ONCOLOGY (2021)
Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker
Elena Fountzilas et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Phenotypic Characteristics of the Tumour Microenvironment in Primary and Secondary Hepatocellular Carcinoma
Petros Fessas et al.
CANCERS (2021)
Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Nabendu Pore et al.
CANCER DISCOVERY (2021)
Dectin-1 Controls TSLP-Induced Th2 Response by Regulating STAT3, STAT6, and p50-RelB Activities in Dendritic Cells
Chao Gu et al.
FRONTIERS IN IMMUNOLOGY (2021)
Biomarkers and Gene Signatures to Predict Durable Response to Pembrolizumab in Non-Small Cell Lung Cancer
Anello Marcello Poma et al.
CANCERS (2021)
Effects of Tobacco Smoking on the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma
Janis V. de la Iglesia et al.
CLINICAL CANCER RESEARCH (2020)
Validation and characterisation of prognostically significant PD-L1+ immune cells in HPV plus oropharyngeal squamous cell carcinoma
Richard J. Young et al.
ORAL ONCOLOGY (2020)
Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-γ-signaling mutant cancer cells
Jason B. Williams et al.
NATURE COMMUNICATIONS (2020)
ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
Ryosuke Okamura et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas
Mario Sanchez-Canteli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) >= 10: a decision centered on empowering patients and their physicians
V. Subbiah et al.
ANNALS OF ONCOLOGY (2020)
A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases
Yanina Jansen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Seven immune-related genes prognostic power and correlation with tumor-infiltrating immune cells in hepatocellular carcinoma
Tiantian Liu et al.
CANCER MEDICINE (2020)
Development and validation of an interferon signature predicting prognosis and treatment response for glioblastoma
Chen Zhu et al.
ONCOIMMUNOLOGY (2019)
Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types
Feng Wang et al.
JAMA ONCOLOGY (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Mechanisms Controlling PD-L1 Expression in Cancer
Jong-Ho Cha et al.
MOLECULAR CELL (2019)
Human papillomavirus and the landscape of secondary genetic alterations in oral cancers
Maura L. Gillison et al.
GENOME RESEARCH (2019)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E. W. Cohen et al.
LANCET (2019)
ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade
Jianfeng Shen et al.
NATURE MEDICINE (2018)
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2018)
Prognostic Significance of PD-L1+ and CD8+ Immune Cells in HPV+ Oropharyngeal Squamous Cell Carcinoma
Benjamin Solomon et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors
Aaron M. Goodman et al.
JAMA ONCOLOGY (2018)
The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis
Wei-fa Yang et al.
ORAL ONCOLOGY (2018)
Frameshift events predict anti-PD-1/L1 response in head and neck cancer
Glenn J. Hanna et al.
JCI INSIGHT (2018)
First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication
Steven Lemery et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Human papillomavirus-related oropharyngeal cancer
M. Taberna et al.
ANNALS OF ONCOLOGY (2017)
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
Weiyi Peng et al.
CANCER DISCOVERY (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer
P. Balermpas et al.
BRITISH JOURNAL OF CANCER (2014)
Foxp3 Treg cells in humoral immunity
James B. Wing et al.
INTERNATIONAL IMMUNOLOGY (2014)
The Role of Cytidine Deaminases on Innate Immune Responses against Human Viral Infections
Valdimara C. Vieira et al.
BIOMED RESEARCH INTERNATIONAL (2013)
Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer
Kai Wang et al.
NATURE GENETICS (2011)
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
K. Kian Ang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
Sian Jones et al.
SCIENCE (2010)
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Jerom Galon et al.
SCIENCE (2006)
分享论文
